ProCE Banner Activity

Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Podcast Episodes
Listen to experts answer questions from a live CCO webinar on best practices in the use of approved BTK inhibitors for treating patients with CLL and MCL and potential uses of emerging investigational BTK inhibitors for these malignancies.

Released: March 31, 2022

Expiration: March 30, 2023

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Matthew S. Davids

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Program Director Disclosure

Program Director

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Lilly, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Lilly, Pharmacyclics, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Lilly, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Lilly, Pharmacyclics, and TG Therapeutics.

Faculty Disclosure

Primary Author

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids MD, MMSc, has disclosed that he has received funds for research support from AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem and consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Nurix, Loxo, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.